Eli Lilly and Company (LLY)vsMeridian Bioscience Inc (VIVO)
LLY
Eli Lilly and Company
$906.70
-1.18%
HEALTHCARE · Cap: $885.28B
VIVO
Meridian Bioscience Inc
$2.24
-5.49%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 19472% more annual revenue ($65.18B vs $333.02M). LLY leads profitability with a 31.7% profit margin vs 12.8%. LLY appears more attractively valued with a PEG of 1.06. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
VIVO
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.6%
Fair Value
$1074.06
Current Price
$906.70
$167.36 discount
Margin of Safety
N/A
Fair Value
$6.53
Current Price
$2.24
$4.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Reasonable price relative to book value
Strong operational efficiency at 22.7%
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.6x book value
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
Revenue declined 13.8%
Earnings declined 13.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : VIVO
The strongest argument for VIVO centers on Price/Book, Operating Margin. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 43.1x leaves little room for execution misses. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : VIVO
The primary concerns for VIVO are P/E Ratio, Market Cap, Revenue Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while VIVO is a declining play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.43 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 48/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Meridian Bioscience Inc
HEALTHCARE · PHARMACEUTICALS · USA
Meridian Bioscience, Inc., a life sciences company, develops, manufactures, distributes and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases and elevated blood lead levels worldwide. The company is headquartered in Cincinnati, Ohio.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?